Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer

作者
Aixa Elena Soyano,Marie Catherine Lee,Hyo Sook Han,Amy L. Aldrich,Hatem Soliman,Sy K. Olson-Mcpeek,Caitlyn Balsay-Patel,Paige M. Aiello,Carly M. Farrell,Robert Jared Weinfurtner,Eliana Burgos,Brian J. Czerniecki,Ganesan Ramamoorthi
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:14 (1): e013590-e013590 被引量:5
标识
DOI:10.1136/jitc-2025-013590
摘要

Patients with metastatic breast cancer (MBC) have limited opportunities for a cure, as they develop resistance to therapies and continually form new metastases. Clinical overt metastases emerge from metastasis-initiating cancer cells (MICs) that disseminate during breast cancer (BC) progression. Currently, there are no available therapies that inhibit MIC dissemination to prevent overt metastasis. We provide preclinical evidence that intratumoral (IT) delivery of type I polarized dendritic cells (DC1) limited the MIC dissemination mechanisms in tumor lesions of human epidermal growth factor receptor 2 (HER2)+ mammary carcinoma. Interferon gamma, a prominent cytokine secreted by T helper 1 and innate-like immune effector cells, inhibited dissemination of MICs from the tumor lesions via the modulation of HER2/progesterone receptor/Wnt family member 4/receptor activator of nuclear factor kappa beta ligand signaling. Importantly, we provide clinical evidence that in patients with stage I-III HER2+ BC, there was significant regression of the primary tumor treated with IT DC1, as well as inhibition of disseminating MIC phenotypes. We observed a reduced burden of MICs in the bone marrow (BM) of patients with stage I-III HER2+BC treated with IT DC1, compared with untreated patients and those treated with standard neoadjuvant HER2 therapies paclitaxel, with or without carboplatin, trastuzumab and pertuzumab (Taxol, Carboplatin, Herceptin and Perjeta or THP). We also treated a single patient with de novo stage IV HER2+ MBC with trastuzumab, pertuzumab and tamoxifen in combination with IT DC1. Remarkably, this treatment resulted in near-complete regression of primary tumor and metastatic disease, along with inhibition of MIC seeding in the BM. These findings suggest an intriguing strategy to inhibit the dissemination of MICs and prevent further overt metastasis in all patients with BC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
唐唐完成签到,获得积分10
刚刚
高高的伯云完成签到,获得积分10
刚刚
ccccc完成签到,获得积分10
1秒前
精明手套完成签到 ,获得积分10
3秒前
3秒前
姜菲菲完成签到,获得积分10
3秒前
Coco完成签到,获得积分10
4秒前
香蕉画板完成签到,获得积分10
5秒前
zhangyiyang完成签到 ,获得积分10
5秒前
香蕉面包完成签到 ,获得积分10
6秒前
wave完成签到,获得积分10
6秒前
天天玩完成签到,获得积分10
7秒前
卷毛君完成签到,获得积分10
7秒前
光亮灯泡完成签到,获得积分10
7秒前
文文武完成签到 ,获得积分10
8秒前
9秒前
gura完成签到 ,获得积分10
10秒前
zdd完成签到 ,获得积分10
11秒前
科研怪兽完成签到 ,获得积分10
11秒前
风中的修杰完成签到 ,获得积分10
11秒前
自然妙旋完成签到,获得积分10
11秒前
机智雅山完成签到 ,获得积分10
12秒前
仁爱的觅夏完成签到,获得积分10
13秒前
等待绮琴完成签到 ,获得积分10
13秒前
长情的寇完成签到 ,获得积分10
14秒前
晅007完成签到 ,获得积分10
14秒前
科研小白毅同学完成签到 ,获得积分10
15秒前
张长弓完成签到 ,获得积分10
15秒前
小鲨宇发布了新的文献求助10
16秒前
Lychee完成签到,获得积分10
16秒前
null的应助被waiting采纳,获得10
17秒前
小金人完成签到,获得积分10
17秒前
南瓜小笨111111完成签到 ,获得积分10
17秒前
小苦瓜完成签到,获得积分10
18秒前
18秒前
csz完成签到,获得积分10
19秒前
Candy完成签到 ,获得积分10
19秒前
JJD完成签到,获得积分10
19秒前
怕孤单的子默完成签到,获得积分10
20秒前
快乐小狗完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719828
捐赠科研通 7748795
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428